Sensus Healthcare Posts Q4 Loss Amid Revenue Decline, Stock Plummets
Sensus Healthcare Inc (NASDAQ:SRTS) reported financial results for the fourth quarter and full year 2025 that fell significantly short of analyst expectations, sending its shares sharply lower in after-hours trading. The medical device company, which specializes in superficial radiotherapy (SRT) systems for treating non-melanoma skin cancer, is navigating a transitional year marked by a strategic shift in its customer base and the recent establishment of new reimbursement codes.
Earnings and Revenue Miss
The company's quarterly performance was notably weaker than Wall Street had anticipated. Sensus reported a net loss of $3.2 million, or $0.19 per share, for the fourth quarter. This contrasted sharply with analyst estimates, which had projected a smaller loss of $0.07 per share. The earnings miss was substantial, with the reported loss per share nearly triple the expected figure.
Revenue for the quarter told a similar story, coming in at $4.9 million. This represented a steep 62% decline from the $13.1 million reported in the prior-year period and missed the consensus revenue estimate of $8.5 million by approximately 42%. The company attributed the year-over-year decline primarily to reduced sales to its historically largest customer.
Key financial misses for Q4 2025:
- Reported EPS: -$0.19 vs. Estimated EPS: -$0.07
- Reported Revenue: $4.9M vs. Estimated Revenue: $8.5M
Full-Year Transition and Strategic Pivot
For the full year 2025, Sensus Healthcare reported revenue of $27.5 million, down from $41.8 million in 2024. The company posted a net loss of $7.7 million, or $0.47 per share, compared to net income of $6.6 million in the previous year. Management emphasized that 2025 was a year of investment and transition, heavily focused on securing new, dedicated Current Procedural Terminology (CPT) codes for SRT treatment, which were published in November 2025.
CEO Joe Sardano highlighted that the new codes provide a per-fraction reimbursement increase of more than 300% compared to the prior delivery code. This development is central to the company's strategy, as it provides "reimbursement certainty and strategic visibility" and improves physician economics. Sardano noted that the improved reimbursement has already begun to catalyze system purchases within the company's Fair Deal Agreement (FDA) program, where treatment volume surged over eight-fold in 2025.
Market Reaction and Forward Outlook
The market's reaction to the earnings report was decisively negative, with the stock dropping approximately 24% in after-hours trading. This sell-off reflects investor disappointment with the significant top- and bottom-line misses during a period the company itself describes as foundational for future growth.
Looking ahead, management provided an optimistic qualitative outlook for 2026, stating its objective is to achieve full-year profitability by leveraging the new reimbursement environment, a more diversified customer base, and international opportunities. For the first quarter of 2026, the company expects system shipments to exceed Q4 2025 levels.
This internal forecast will soon be tested against Wall Street's expectations. Analysts currently estimate a Q1 2026 loss of $0.06 per share on revenue of $8.4 million. For the full year 2026, the consensus estimate projects a loss of $0.06 per share with sales of $40.6 million. Sensus's ability to meet or exceed these estimates will be critical in rebuilding investor confidence after the Q4 shortfall.
Balance Sheet and Operational Highlights
Despite the operational loss, Sensus Healthcare maintains a solid balance sheet, ending the year with $22.1 million in cash and cash equivalents and no debt. This financial position provides runway to execute its 2026 plan. Operationally, the company shipped 70 SRT systems during 2025, with 56 in the U.S. and 14 internationally. The fourth quarter saw 14 shipments, including six international units, achieved without any contribution from its largest historical customer.
Conclusion
Sensus Healthcare's fourth-quarter results underscore the challenges of a business in transition. While the establishment of dedicated CPT codes represents a significant long-term victory for the company's commercial strategy, the immediate financial impact has been a severe revenue contraction and deeper-than-expected losses. The steep after-hours decline in the stock price indicates the market is prioritizing current earnings performance over future potential. The company's path to a recovery in shareholder value now hinges on its ability to rapidly convert its improved reimbursement landscape into sustained sales growth and a return to profitability in the coming quarters.
For a detailed look at upcoming earnings estimates and historical performance, view the Sensus Healthcare earnings and estimates page here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, nor does it recommend buying or selling any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
